The complexities of adjuvant therapy in melanoma

Melanoma Insights for Professionals

The success of immunotherapy and targeted therapy in the treatment of advanced melanoma has led to the same therapies being used in the adjuvant setting to reduce the risk of recurrence.

In this podcast, A/Prof Matteo Carlino interviews fellow Medical Oncologist A/Prof Alexander Menzies on the evidence for adjuvant therapy to guide clinical decision-making. Understanding the complexities of adjuvant therapy is key to identifying and managing patients suitable for this treatment. Topics covered in this discussion include:

• Weighing up the risk-benefit ratio in the use of adjuvant therapy
• Patient populations who are not suitable for adjuvant therapy
• Treating BRAF-mutant patients - which option is best?
• Adjuvant treatment for mucosal melanoma
• Follow-up imaging after adjuvant therapy to identify recurrence and toxicities
• The diminished role of completion lymph node dissection
• The role of adjuvant radiotherapy
• Adjuvant therapy in Stage II melanoma
• Neoadjuvant therapy
• Management of recurrences on or after adjuvant therapy

This podcast is suitable for Oncologists, Oncology Nurses and other healthcare professionals.

Please note that this podcast was accurate at the time of recording (Feb 2021) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

SPEAKERS:

• A/Prof Alexander Menzies - Medical Oncologist, Melanoma Institute Australia, Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of Sydney
• A/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia, Westmead and Blacktown Hospitals Clinical Associate Professor, The University of Sydney